An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine

Clinical Therapeutics

Volumn 25, Issue 1, 2003, Pages 210-224

  Schoen, Robert T ^a   Deshefy Longhi, Terry ^a   Van Hoecke, Christian ^b   Buscarino, Charles ^b   Fikrig, Erol ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Booster immunization; Lyme disease; Recombinant outer surface protein A vaccine

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; LYME DISEASE VACCINE; RECOMBINANT OUTER SURFACE PROTEIN A VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ENDEMIC DISEASE; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LYME DISEASE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PAIN; PHARYNGITIS; PROSPECTIVE STUDY; RASH; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION; VACCINATION;

EID: 0037274138     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)90027-0     Document Type: Article

References (17)

1. Lyme disease - United States, 1996. Morb Mortal Wkly Rep. 1997;46:531-535.
2. Meek JI, Roberts CL, Smith EV Jr, Cartter ML. Underreporting of Lyme disease by Connecticut physicians, 1992. J Public Health Manag Pract. 1996;2:61-65.
3. Coyle BS, Strickland GT, Liang YY, et al. The public health impact of Lyme disease in Maryland. J Infect Dis. 1996;173:1260-1262.
4. Lyme disease - United States, 1999. Morb Mortal Wkly Rep. 2001;50:181-185.
5. Nocton JJ, Steere AC. Lyme disease. Adv Intern Med. 1995;40:69-117.
6. Steere AC, Sikand VK, Meurice F, et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N Engl J Med. 1998;339:209-215.
7. Van Hoecke C, Lebacq E, Beran J, Parenti D. Alternative vaccination schedules (0, 1, and 6 versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine. Clin Infect Dis. 1999;28:1260-1264.
8. Schoen RT, Sikand VK, Caldwell MC, et al. Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 12 months. Clin Ther. 2000;22:315-325.
9. Feder HM Jr, Beran J, Van Hoecke C, et al. Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children. J Pediatr. 1999;135:575-579.
10. Beran J, De Clercq N, Dieussaert I, Van Hoecke C. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old. Clin Infect Dis. 2000;31:1504-1507.
11. Sikand VK, Halsey N, Krause PJ, et al. Safety and immunogenicity of a recombinant Borrelia burgdorferi outer-surface protein A vaccine against Lyme disease in healthy children and adolescents: A randomized controlled trial. Pediatrics. July 2001;108:123-128.
12. Parenti D, Gillet M, Sennewald E, et al. Correlate of protection for Lyme disease (LD) using LYMErix™, recombinant, adjuvanted Borrelia burgdorferi outer-surface lipoprorein A (L-OspA) vaccine. Presented at: Infectious Disease Society of America Annual Meeting; November 12-15, 1998; Denver, Colorado. Abstract 705.
13. Van Hoecke C, Comberbach M, De Grave D, et al. Evaluation of the safety, reactogenicity, and immunogenicity of three recombinant outer-surface protein (OspA) lyme vaccines in healthy adults. Vaccine. 1996;14:1620-1626.
14. Karpinski KF, Hayward S, Tryphonas H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA). J Immunol Methods. 1987;103:189-194.
15. Reporting Adverse Drug Reactions: Definitions of Terms and Criteria for their Use. Geneva, Switzerland: World Health Organization; 1999.
16. Gross DM, Forsthuber T, Tary-Lehmann M, et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science. 1998;281:703-706.
17. Sigal LH, Zahradnik JM, Lavin P, et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. N Engl J Med. 1998;339:216-222.